To heighten interest in kidney disease throughout society, Health and Global Policy Institute (HGPI) began the Kidney Disease Control Promotion Project in 2022 to help build momentum for promoting more effective and organic kidney disease countermeasures. As the first proposal from this project, we have formulated the following emergency recommendations based on hearings with specialists in each field.

Issues and discussion points for advancing kidney disease control

1. The fact that prevention and early intervention for chronic kidney disease (CKD) is an important foundation for healthy longevity must be reaffirmed and comprehensive countermeasures for CKD that are linked to other chronic diseases must be taken.
2. In addition to interventions from medical specialists, advancing kidney disease control will require collaboration among related parties in the healthcare system and during various phases of health promotion measures with involvement from a broad range of collaborators.
3. Community- and prefecture-based best practices in kidney disease control are beginning to emerge and there are high expectations for them to be shared and expanded horizontally.
4. Kidney disease control measures that are based on the perspectives of patients and other affected parties must be advanced.

For details, please see the PDF linked below.

Future developments in the Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration

To more strongly connect past efforts in the field of kidney disease from industry, Government, academia, and civil society to concrete results, while referring to best practices, good examples, and lessons from communities, HGPI will identify necessary measures for nationwide equity in kidney disease control and generate recommendations on an ongoing basis. By holding wide-ranging discussions that examine pharmaceutical therapy as well as encompass efforts to promote behavioral change among affected parties and include the concept of social prescriptions, we will build momentum for greater awareness toward kidney disease countermeasures throughout society. When advancing this project, we will meet with our multi-stakeholder advisory board that includes patients and other affected parties to hold meetings with the theme of “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” and synthesize discussion points.

• Advisory board members (Titles omitted; in alphabetical order)

• Naoki Kashihara (Chairman, Japanese Society of Nephrology; Vice President, Kawasaki Medical School; Professor, Department of Nephrology/Hypertension, Kawasaki Medical School)
• Yukie Kitajima (Associate Professor, Division of Medical Nutrition, Faculty of Healthcare, Tokyo Healthcare University)
• Kiyoshi Kurokawa (Chairman, HGPI)
• Yoko Miyamoto (Standing Director, Japan Association of Kidney Disease Patients; Person living with a kidney disease)
• Toshiki Moriyama (Professor, Health and Counselling Center, Osaka University)
• Masashi Mukoyama (Professor, Department of Nephrology, Faculty of Life Sciences, Kumamoto University)
• Takeshi Shukunobe (CEO, PPeCC; Person living with a kidney disease)
• Koichi Tamura (Head, Department of Medical Science and Cardiorenal Medicine, Graduate School of Medicine, Yokohama City University)
• Keitaro Yokoyama (Professor, School of Medicine, Jikei University; Director, Jikei University Harumi Toriton Clinic)

*These recommendations were compiled by HGPI based on the aforementioned hearings in its capacity as an independent health policy think tank. They should not be taken to represent the opinions of any specific advisory board member or other related party, or any organization to which they belong.